Anika TherapeuticsANIK +2.96%64 Days Payable is 53.21 as of Mar. 2026, which is 0% below its 10-year median of 53.40. GuruFocus rates ANIK with a GF Score™ of 64/100 and a GF Value™ of $20.58 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Anika Therapeutics ranks worse than 83.08% on this metric.
The historical rank and industry rank for Anika Therapeutics's Days Payable or its related term are showing as below:
ANIK'
s Days Payable Range Over the Past 10 Years
Min: 38.07 Med: 53.4 Max: 80.55
Current: 41.19
During the past 13 years, Anika Therapeutics's highest Days Payable was 80.55. The lowest was 38.07. And the median was 53.40.
ANIK's Days Payable is ranked worse than 83.08% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs ANIK: 41.19
Anika Therapeutics's Days Payable
increased
from Mar. 2025 (43.27) to Mar. 2026 (53.21).
It may suggest that Anika Therapeuticsdelayed paying its suppliers.
Anika Therapeutics Days Payable Related Terms
Anika Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Anika Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (ANIK) has a Days Payable of 53.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anika Therapeutics and its competitors. This is near median its historical median of 53.40. Over the past decade, Anika Therapeutics' Days Payable has ranged from 38.07 to 80.55. According to the industry distribution chart, Anika Therapeutics ranks #766 out of 922 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is Anika Therapeutics' Days Payable too high?
Anika Therapeutics' current Days Payable of 53.21 is near median its 10-year median of 53.40. Over the past 10 years, this metric has ranged from a low of 38.07 to a high of 80.55. The Drug Manufacturers industry median Days Payable is 90.61. Anika Therapeutics' value of 53.21 is 41.3% below this industry median. Based on the distribution chart, Anika Therapeutics ranks #766 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Days Payable compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #766 out of 922 companies for Days Payable. This places Anika Therapeutics in the lower half of its industry. The industry median Days Payable is 90.61. Anika Therapeutics' value of 53.21 is 41.3% below this benchmark. Historically, Anika Therapeutics' own Days Payable has ranged from 38.07 to 80.55 over the past decade. While the company's 10-year median is 53.40 vs. the industry median of 90.61, Anika Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current Days Payable of 53.21 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Days Payable is 53.21, which is near median its own 10-year median of 53.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.58, compared to a current price of $16.30 — trading 20.8% below its estimated fair value. The current Days Payable is 53.21, which is near median its 10-year median of 53.40 and 41.3% below the Drug Manufacturers industry median of 90.61. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Days Payable is 53.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of $16.30 is trading 20.8% below its estimated GF Value™ of $20.58.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for ANIK:
Days Payable: 53.21 (near median its 10-year median of 53.40)
GF Value™: $20.58 vs. price of $16.30 (20.8% below fair value)
Industry Position: 41.3% below the Drug Manufacturers median (#766 of 922)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score
Get the complete analysis for ANIK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
